Categories
Sanity Group

Sanity Group welcomes aspects of the official document outlining the key points on cannabis legalization, but sees room for improvement

“We are very pleased that the German government is actively pushing ahead with the planned cannabis legalization. Today’s published key positions paper is a first step that needs to be refined in the course of the parliamentary process. Many of the cornerstones are in line with our expectations, such as the elimination of a THC ceiling, strict age controls on dispensing in licensed stores, and the removal of cannabis from the Narcotics Act. Other points such as a general ban on advertising and lack of import possibilities from other countries do not make sense from our point of view, especially in terms of fighting the illicit market and to meet the market demand,” says Finn Hänsel, founder and CEO of Berlin-based cannabis company Sanity Group.

In detail, the company expressly welcomes the fact that cannabis will no longer be legally classified as a narcotic in Germany in the future. However, a simultaneous regulatory adjustment of medical cannabis would also be necessary from the point of view of Sanity Group, as the legalization of recreational cannabis is likely to have a massive impact on this area as well. With the continuing obstacles to reimbursement for medical cannabis, there is a particular danger that patients will treat themselves with recreational cannabis without medical advice.

The Sanity Group takes a positive view of dispensing in licensed specialist stores, and possibly pharmacies, as well as the proposal to examine specialist stores with consumption facilities where specialist care and advice can be ensured. The Sanity Group welcomes strict proof of age checks at all sales outlets, as well as the obligation to provide proof of expertise and proof of specific advisory and prevention skills, as well as the appointment of a contact person for the protection of minors at each sales outlet. Sanity Group supports the approaches tasked with protecting and preventing use amongst minors in their entirety. 

“Unfortunately, ecommerce sales are no longer envisaged for the time being in the updated key positions paper. However, it is precisely this that can make a major contribution to displacing the illicit market, as it is the only way to serve rural regions,” says Sanity Group founder Finn Hänsel, who would also like to see a wide variety of products – according to the key issues paper, the government wants to allow dosage forms for smoking, inhalation, nasal and oral intake in the form of capsules, sprays and drops. Edibles are not to be allowed initially. “By restricting the dosage forms, you give the illicit market a gateway to offer more edibles in the future,” Hänsel points out.

The entrepreneur is pleased that a possible THC cap is not being considered: “A limit on the THC content would have meant that the illicit market would continue to flourish with high-percentage THC products and many consumers would not even switch from the illegal to the legal market. Therefore, a limit would have been counterproductive.”

His company welcomes the exemption from punishment for the purchase and possession of cannabis for personal use in private and public spaces, regardless of the specific THC content and origin, as well as the possibility of personal cultivation for private individuals and the discontinuation of ongoing investigations and criminal proceedings, which is a “correct and important signal”.

The Sanity Group also welcomes the fact that cultivation in greenhouse facilities or indoors is to be made possible in Germany. However, Sanity Group sees it as problematic that cultivation is apparently to take place exclusively in Germany due to legal conditions at EU and international level: “National demand will not be able to be met by German production alone. Production in Germany is also expensive and very energy-intensive, which will have an impact on the selling price. Importing from EU and non-EU countries must therefore be made possible in our view to meet demand and push back the illicit market – especially immediately after implementation of legalization,” says CEO Finn Hänsel, who believes the influence of findings from other countries where cannabis is already legalized is essential. In Canada, for example, it took domestic producers a long time after legalization to ramp up production to meet demand, which eventually benefited the illicit market. Sanity Group would like to see further legal scrutiny and search for solutions on this issue.

The company also takes a critical view of a general advertising ban: although a restriction in the area of advertising is perfectly understandable for reasons of youth protection, a general advertising ban is not conducive to the development of an enlightened consumer base. Finn Hänsel: “In our view, a complete advertising ban is not conducive, since product information is essential for education and destigmatization. A completely new legal market is developing in which consumers must orient themselves responsibly. In order for them to be able to make an informed and considered purchase decision, it is also necessary for suppliers to be able to distinguish themselves from one another, e.g. through product design and informative advertising materials. In addition, it should be expected that the illicit market will make moves to differentiate and improve its product selection. A clear way to do this would be through branded packaging. If recreational cannabis that is sold legally is subject to similar packaging and restrictive marketing rules, this will provide the illicit market with a clear advantage which is something we need to avoid.”

The Sanity Group sees the proposed tax model based on THC content as fundamentally positive due to the health policy steering effect, but emphasizes again that the total price for cannabis including all taxes must be competitive with the illegal market (about ten euros per gram). The company also believes that part of the taxes should be used for the protection of young people and target-group-specific measures for education and addiction support.

About Sanity Group
Berlin-based Sanity Group aims to improve people’s quality of life through the use of cannabinoids and the endocannabinoid system. In addition to pharmaceuticals, the focus is also on wellbeing and cosmetic products that utilize cannabinoids. Sanity Group, founded in Berlin in 2018 by Finn Age Hänsel and Fabian Friede, includes Vayamed and AVAAY Medical (medicinal cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), Belfry Medical (medical products and digital applications), VAAY (wellbeing) and This Place (natural cosmetics). Near Frankfurt am Main, Sanity Group also operates a production and processing facility for cannabis extracts. More information can be found on sanitygroup.com/press.

Headerimage: Sanity Group // Screenshot: bundesgesundheitsministerium.de

Categories
Sanity Group

German Cannabis company Sanity Group announces $37.6 Million Series B funding round

The new investment will fuel Sanity Group’s growth, enable European expansion and strengthen research and development activities. 

“This funding is an important milestone for us and a strong signal towards the future of cannabis in Germany and Europe. I am grateful for the belief shown by both new and existing investors. Our goal is to leverage the full potential of the cannabis plant and to explore and harness the different cannabinoids – with the new capital, we will be able to accelerate our medical and consumer business units whilst preparing accordingly for cannabis legalization in Germany,” said Finn Age Hänsel, Founder and Chief Executive Officer of Sanity Group.

“This financing round is not only the largest funding round achieved by a European cannabis company to date, but also one of the few upsizing rounds in this current economic phase of the German startup scene. Against the backdrop of a challenging global economy, we are proud to have achieved a funding round of this magnitude, facilitating the pursuit and progress of our mission to become a significant cannabis brand in Germany and Europe”, added Max Narr, Chief Investment Officer of Sanity Group.

“Our mission is to help aspiring companies become tomorrow’s market leaders. We invest in curious minds with a shared passion to innovate. We have felt this passion from the Sanity Group team since our involvement in the summer of 2021, and we look forward to accompanying their further development in the future”, said Michael Sidler, Partner at Swiss VC Redalpine, lead investor in the Series A financing round in 2021.

Karan Wadhera, Managing Partner at Casa Verde Capital, added: “Sanity Group is already the most well capitalized cannabis business in Germany and is on track to become one of the leading brands in Europe. We are thrilled with their continued progress and will keep offering financial and operational support as they scale.”

Sanity Group was founded in 2018 and has around 120 employees in the medical, consumer health and science sectors now. The company aims to improve quality of life through the use of cannabinoids. The focus is on pharmaceuticals, medical products and consumer goods. Sanity Group’s existing investors include music producer Will.I.Am (Black Eyed Peas), Hollywood actress Alyssa Milano, manager Scooter Braun, Swiss VC Redalpine, Casa Verde Capital, HV Capital, Calyx, TQ Ventures, Atlantic Food Labs, Cherry Ventures, Bitburger Ventures, SevenVentures, GMPVC, Navy Capital and SOJE Capital.

About Sanity Group
Berlin-based Sanity Group aims to improve people’s quality of life through the use of cannabinoids and the endocannabinoid system. In addition to pharmaceuticals, the focus is also on wellbeing and cosmetic products that utilize cannabinoids. Sanity Group, founded in Berlin in 2018 by Finn Age Hänsel and Fabian Friede, includes Vayamed and AVAAY Medical (medicinal cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), Belfry Medical (medical products and digital applications), VAAY (wellbeing) and This Place (natural cosmetics). Near Frankfurt am Main, Sanity Group also operates a production and processing facility for cannabis extracts. More information can be found on sanitygroup.com/press.

*This investment was made by BT DE Investments Inc., a wholly owned BAT Group company. For further information about BAT, visit BAT.com.

Picture: Sanity Group

Categories
Sanity Group

Portugal, South Africa and Canada: Sanity Group strengthens and diversifies its global partner network

Sanity Group’s new partners for medicinal cannabis flos include the South African suppliers FarmaGrowers, Chroni-Co and Safri Canna, the Canadian suppliers Groupe Fuga, Habitat Life Sciences, Candre Cannabis and Miracle Valley, as well as Cannexpor Pharma from Portugal. To expand its sourcing options, Sanity Group’s medical division is also partnering with Portugal-based MHI Cultivo Medicinal, a subsidiary of MediCane Health Inc, thereby actively integrating a licensed platform for EU GMP processing of cannabis flos into its network.
To strengthen its market position in dronabinol and active ingredient development, Sanity Group has also entered into an exclusive partnership with GESLabs, a South African innovation company based in Cape Town, for the production of innovative dronabinol products and cannabis isolates.

Overall, by expanding its supplier network and establishing new innovation and value-added partnerships, Sanity Group is expanding its leading position in medical cannabis products and strengthens its pole position for the planned legalization of cannabis for adult-use in Germany.

“We looked at over 200 potential partners worldwide. In addition to product quality and process reliability, the new partners impressed us with their sustainable corporate governance and their enthusiasm for cannabis,” says Thimo V. Schmitt-Lord, Director Innovation & New Markets at Sanity Group.

About Sanity Group
Berlin-based Sanity Group aims to improve people’s quality of life through the use of cannabinoids and the endocannabinoid system. In addition to pharmaceuticals, the focus is also on wellbeing and cosmetic products based on cannabinoids. Sanity Group, founded in Berlin in 2018 by Finn Age Hänsel and Fabian Friede, includes Vayamed and AVAAY Medical (medicinal cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), Belfry Medical (medical products and digital applications), VAAY (wellbeing) and This Place (natural cosmetics). Near Frankfurt am Main, Sanity Group also operates a production and processing facility for cannabis extracts. More information at sanitygroup.com/press.

About Chroni-Co
Chroni-Co is a South African producer of high quality craft cannabis for the medical and pharmaceutical industry. The family business has been farming for over ten generations and follows the mantra: Old school values, New school visions. As dedicated preservationists of the land, the belief in living honestly, respectfully and with integrity in harmony with Mother Nature is upheld with the goal of producing the highest quality handcrafted cannabis for the medical and pharmaceutical industries to support research, and to promote non-harmful alternatives for pain management, mental health and chronic diseases. For more information, visit www.chroni-co.com.

About GESLabs
GESLabs is a cGMP pharmaceutical manufacturing business specializing in alkaloid and cannabinoid active pharmaceutical ingredient manufacture. Using carefully cultivated, (GACP), biomass processed through world-class technology GESLabs can deliver best-in-class active pharmaceutical ingredients for use in prescription medicines and wellness supplements. Find out more at www.geslabs.com.

About SafriCanna
SafriCanna is a South African medical cannabis company focused on the cultivation, processing and export of high-grade medical cannabis flowers to international markets. It is the first and largest purpose built EU-GMP cannabis cultivator in South Africa and is on track to become the largest exporter of dry flower out of the Southern hemisphere. The company’s vision is to be the leading Southern hemisphere certified medical cannabis producer, by bringing together global best practices and unique South African advantages. SafriCanna has already established strategic distribution partnerships with the leading cannabis importers / distributors in Germany, UK, Israel and Australia. For more information, visit www.safricanna.com.

About Cannexpor Pharma 
Cannexpor Pharma is an EU-based group of companies with an indoor pharmaceutical facility in Portugal that intends to supply pharma grade cannabis products to our partners and patients worldwide. Our focus is the quality of the product that we produce. Our indoor cannabis cultivation techniques and strict quality control allow us to achieve extreme purity of cannabis flowers, consistency of the selected cannabis genetics, and superior cannabinoid and terpene profiles. Find out more at cannexpor.com.

About MHI Cultivo Medicinal
Founded in 2019, Incorporated in Canada with presence in Israel, Portugal, Germany and Australia, MediCane’s seed-to-customer business model allows comprehensive monitoring and control of the cultivation process, along with subsequent medical and pharmaceutical R&D. This model includes genetic seed development, plant propagation and cultivation, manufacturing, pharmacological development, medical research, and distribution of the final products to end-users. The genetic bank contains a variety of strains that are cultivated in MediCane’s state-of-the-art greenhouses and then processed in post-harvest and manufacturing facilities under GACP and EU- GMP quality standards. The distribution of the final products to end-users is carried out through a global BTB and BTC partner network. In addition, through its EU-GMP premises in Portugal, MediCane Health Inc. provides contract manufacturing services for EU-GMP premium cannabis based preparations and substances, enabling premium pharma-grade and pharma-kraft cultivators around the world to meet the stringent European Good Manufacturing Practices standards and regulations for the health and wellbeing of patients. More information at www.medicane.net.

About FarmaGrowers
Established in 2019 in the North West Province of South Africa, FarmaGrowers specializes in the cultivation, manufacturing (curing) and exporting of Medicinal Cannabis. The vision is to provide the best quality EU GMP Medicinal Cannabis for export. FarmaGrowers aims to build lasting relationships with clients globally and be known as a market leader in a groundbreaking new industry. Leveraging the unique climate of Southern Africa as well as cutting edge technology and international experience, FarmaGrowers strives for sustainable growth and leaving an unforgettable, yet environmentally friendly footprint in the Medicinal Cannabis Industry, locally as well as internationally. For more information, visit www.farmagrowers.co.za.

About Candre Cannabis
Candre Cannabis Inc., based in Sundre, Alberta, Canada, is a licensed craft cannabis producer focused on providing high-quality, in-demand cannabis products for medical and recreational use. Candre’s indoor facility built specifically for the production of premium quality cannabis is designed with 12 completely isolated grow rooms equipped with state-of-the-art technology including three tier mobile vertical grow infrastructure which triples the overall cannabis canopy. Find out more on www.candrecannabis.com.

About Habitat Life Sciences
Canadian Habitat Life Sciences Inc. is focused on innovative, sustainable agriculture technology that is environmentally thoughtful and economical. Using cutting-edge technology and techniques, the company aims to revolutionize agriculture with an innovative approach to vertical growing and aquaponics that conserves land, water and air. Aquaponics is a production system that combines aquaculture, the cultivation of aquatic organisms, with hydroponics, the cultivation of plants in nutrient-enriched water. Habitat’s proprietary know-how and technology connects aquaculture waste streams to integrated hydroponic greenhouse infrastructure inputs resulting in an environmentally sustainable and economically profitable aquaponics system. To achieve its vision of balancing environmental stewardship with profitability in the production of both food and recreational cannabis, Habitat has assembled a team of leading edge aquaponics experts, horticultural experts, and business leaders. They believe that responsibly and sustainably grown products should not only nourish your body, they should nourish your mind, your community, and your habitat. For more information, visit www.habitat.life.

About Groupe Fuga
Groupe Fuga is a private corporation based in Stoneham, near Québec City, Canada. Philippe Laperrière is the company’s CEO. On an area of just over 8,600 square meters, Fuga grows cannabis in small batches, in living soil that is enriched with organic matter, in order to enhance its properties while favouring the health of both users and the staff. Fuga’s approach is clear and resolutely turned towards the future of this field: The company is much more interested in the entourage effect derived from the interactions with terpenes than in the race to produce cannabis with the highest THC level. 1% of the revenue is donated to the community for social projects. For more information, visit www.fuga.ca.

About Miracle Valley Medicinal Alternatives
Miracle Valley is a fully operational, cultivation focused facility licensed under the Cannabis Act of Canada with the goal to provide the highest quality cannabis products available. The British Columbian based company established to produce, process, package and distribute bulk and finished cannabis to domestic and international distributors. Miracle Valley is driven by a passion for leadership and a commitment to being a world-class employer. Miracle Valley’s team combines decades of experience growing true legacy craft strains with the most advanced tech in picturesque Mission, British Columbia. Their mission: To be a top tier provider of cannabis products and set the standard for premium cannabis cultivation. For more information, visit www.miraclevalley.ca.

Picture: Shutterstock

Categories
Sanity Group

Sanity Group has expanded its management team

Dr. Konstantin Rutz has joined the Sanity Group after more than five years at Boston Consulting Group (BCG), where he was a project manager in the Health Care division. He has taken over as Managing Director of Sanity Group’s Medical division. The 36 year old lawyer has several years of experience in the pharmaceutical, life science and medtech sectors and has most recently been particularly involved in pharmaceutical commercial issues.

Alongside Dr. Konstantin Rutz, Tobias Wirth has also joined Sanity Group: He has more than 15 years of sales experience in the pharmaceutical sector, particularly in the indication areas of pain and oncology as well as in the area of medical cannabis, and is now responsible for sales and marketing at Sanity Group’s Medical division. He spent eight years at Teva GmbH in various management roles and was most recently at Cannamedical Pharma GmbH, before joining Sanity Group.

Since May 2022, Laura Simonow, Founder of the functional natural cosmetics brand This Place, has been Managing Director of the Consumer Health division Sanity Care with the brands This Place and VAAY.

Florian Blaschke joined Sanity Group in January 2022 as Chief Finance Officer, responsible for the Group’s finances. Max Narr, who has been with the Sanity Group since 2020 and is Managing Director of the joint venture Endosane Pharmaceuticals, is responsible for Strategy and M&A at Sanity Group as Chief Investment Officer.

The new management structure is also due to the decision of Sanity Group co-founder Fabian Friede to step down from the operational side of the business for personal reasons. Friede will remain with the company as a shareholder and advisor.

About Sanity Group
Berlin-based health and life science company Sanity Group aims to improve people’s quality of life through the beneficial use of cannabinoids and the utilization of the endocannabinoid system. The focus is on cannabinoid-based pharmaceuticals and consumer goods. In parallel, Sanity Group is also working and researching new medical products, innovative dosage forms, and technological products and services. Sanity Group, founded in Berlin in 2018 by Finn Age Hänsel and Fabian Friede, includes Vayamed and AVAAY Medical (medical cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), Belfry Medical (medical products and digital applications), VAAY (wellbeing) and This Place (functional natural cosmetics). Near Frankfurt am Main, Sanity Group operates a production facility for cannabis extracts. More information at sanitygroup.com/press.

Image: Sanity Group – Maximilian König (c)

Categories
Vayamed

Vayamed Cannakits®: Innovative cannabis formulation kits enable new forms of application for an expanded therapy spectrum – experienced therapists sought for clinical support survey

The special formulation sets are available in three variants for the standardized production of nasal spray emulsion, vaginal suppositories and rectal suppositories (cannabis extracts are not included): Vayamed Cannakit® Nasal Spray is designed to support rapid onset of action through absorption at the nasal mucosa and offers a simple alternative to oral or inhaled dosing that can be used discreetly in everyday life. Vayamed Cannakit® vaginal suppositories are intended to enable new therapeutic approaches in women’s health: Vaginal application offers an alternative to oral or inhaled dosing and also has the potential to open up new therapeutic areas such as the treatment of endometriosis symptoms, PMS or inflammation. Vayamed Cannakit® rectal suppositories are designed to offer an alternative when oral or inhaled forms of dosage are more difficult, for example for patients who are terminally ill.

First market version available – experienced therapists sought for clinical support survey

“After almost two years of development, we are very proud to be the first medical cannabis company in Germany to offer these alternative dosages in cannabis therapy. The new therapy options of the Vayamed Cannakits® are intended to benefit especially those patient groups for whom no optimal cannabis therapy has been possible so far due to a lack of alternative dosage forms, for example in palliative care or women’s health,” says Thimo V. Schmitt-Lord, Director New Markets & Innovation in the medical sector of Berlin-based Sanity Group, to which Vayamed belongs.

The first version of the Vayamed Cannakits®, which is now available in pharmacies, is specifically aimed at physicians with cannabis therapy experience, who would like to use the product on selected patients in individual therapy trials and thus contribute to further product development and casuistry developments.
Doctors who would like to receive more information and participate in a standardized evaluation of the use of the product in clinical practice can contact Vayamed at medical@vayamed.com.
Further information about the Vayamed Cannakits® is also available online at www.vayamed.com/cannakits.

About Vayamed
Vayamed specializes in the development and distribution of innovative cannabinoid-based medicinal products for the European market and is committed to making medicinal cannabis widely available to physicians, pharmacists and patients. To this end, Vayamed works with an established network of international partners. Vayamed is part of the Sanity Group, a health and life science company based in Berlin, Germany, dedicated to the medical and healthcare use of cannabinoids. For more information, visit www.vayamed.com and www.sanitygroup.com/press.

Image: Vayamed / Sanity Group (c)

Categories
Sanity Group Sanity Medical

Sanity Group at the hemp fair Mary Jane and ICBC Berlin 2022

More than 300 exhibitors will present their brands and products to more than 30,000 expected visitors at Mary Jane, Germany’s largest hemp fair, at the Arena in Berlin-Treptow on the weekend of July 15-17, 2022. The Sanity Group is represented with its two brands AVAAY Medical and VAAY in the main hall at booth 53 (near the beach and outside area) and shows its CBD products and informs about the diverse topics and possibilities of cannabis. For industry visitors such as physicians and pharmacists, expert advisors will be available to answer questions on all topics related to medical cannabis.
Every year, Mary Jane Berlin presents the latest developments and products related to the hemp plant. In addition to the trade fair, the supporting program also includes conferences, lectures and discussions by national and international hemp experts on topics such as cannabis legalization and the medical use of cannabis. For more information on Hemp Fair 2022, visit www.maryjane-berlin.com.

Sponsor at Europe’s largest B2B industry event ICBC

On July 19 and 20, 2022, the International Cannabis Business Conference (ICBC), Europe’s oldest and largest B2B industry trade show and conference, will then take place at Berlin’s Estrel Hotel in Neukölln. As a major networking event for the European cannabis industry, the event attracts around 350 sponsors and exhibitors as well as 500 participants from over 80 countries. There is an extensive program with many interesting speakers. On July 19 at 11:15 a.m., for example, there will be a panel discussion on “Cannabis Legalization on the Horizon in Germany” with Antonia Menzel, Director Public Affairs at Sanity Group, among others. Sanity Group is also one of the sponsors of the event and will be present in Convention Hall 2 at booth 136 with its medical cannabis brands AVAAY Medical and Vayamed. There, the expert consultants of the Berlin-based company will inform industry trade visitors such as physicians and pharmacists about all topics in the field of medical cannabis.
The ICBC is considered the “go to” event for the industry and anyone interested in the business and investments surrounding the fast-growing industry. For more information on ICBC, visit www.internationalcbd.com.

 

About Sanity Group
The Berlin-based health and life science company Sanity Group has set itself the goal of improving people’s quality of life through the sensible use of cannabinoids and the utilization of the endocannabinoid system. In addition to pharmaceuticals, the focus is also on wellbeing and cosmetic products based on cannabinoids. In parallel, Sanity Group is also working and researching new medical products, innovative dosage forms, and technological products and services to further develop the infrastructure. Sanity Group, founded in Berlin in 2018 by Finn Age Hänsel and Fabian Friede, includes Vayamed and AVAAY Medical (medical cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), Belfry Medical (medical products and digital applications), VAAY (wellbeing) and This Place (functional natural cosmetics). Near Frankfurt am Main, Sanity Group also operates a production facility for cannabis extracts and processing. More information at sanitygroup.com/press.

Categories
Sanity Medical Vayamed

Vayamed and telemedicine pioneer Telaleaf launch exclusive partnership

Telaleaf, a telemedicine company transforming the access and delivery of medical cannabis care to patients, and Berlin-based medical cannabis brand Vayamed are pleased to announce a strategic partnership to strengthening the quality of telemedicine services in cannabis therapy in Germany through premium quality virtual care and to improve access, in line with Vayamed’s brand vision: “Medicine from Nature. Customized for Patients”. Vayamed and Telaleaf are driven by the vision that telemedicine will continue to move healthcare delivery from clinic to home, and will become the standard in cannabis-based medicine. Doctor visits to consult about Vayamed products and treatment options are planned as well as further programs in the field of talent support and further training at leading medical faculties nationwide. 

“The importance of telemedicine in the German healthcare system will continue to grow. It offers many benefits for doctors, patients and the healthcare system, for example better access and treatment quality, qualified trainings, and improved health insurance reimbursement levels through special training offers for doctors. Together with Telaleaf, we want to improve therapies with medical cannabis in Germany through the utilization of telemedicine”, said Thimo V. Schmitt-Lord, Director New Markets & Innovation at Vayamed.

“In order to fully realize the vision of cannabis-based medicine as the advanced, alternative medicinal modality it has proven to be, Telaleaf has entirely reimagined the cannabis healthcare delivery model such that all necessary medical services, tools and resources come together for patients and doctors under one unified field. Our joint mission with Vayamed is to drive better health outcomes for patients with personalized virtual care that is sustained by expert-led medicinal cannabis training and education,” said Telaleaf CEO Gavin Treanor.

Telaleaf collaborates with leading experts such as Prof. Kirsten Müller-Vahl, M.D., and Franjo Grothenhermen, M.D., and the medical cannabis training for participating doctors is provided at the highest educational level in cooperation with Dresden International University.

 

About Vayamed 
Medical cannabis specialist Vayamed, a brand of Berlin-based health and life science company Sanity Group, specializes in the development and distribution of innovative cannabinoid-based medicinal products for the European market and, as a reliable provider, is committed to making medical cannabis accessible to doctors, pharmacists and patients. 

About Telaleaf
Telaleaf is a telemedicine company transforming the delivery of cannabis care by connecting patients to expert doctors, trained in cannabis-based medicine, who conduct virtual medical visits and provide personalized treatment plans. Our aim is to improve patient outcomes, by improving the patient experience with high quality treatment, ease of access and expert-led training to doctors, for the most advanced virtual care in cannabis medicine.

Categories
Endosane Sanity Medical

Endosane and UCI investigate the efficacy of new compounds for the treatment of PTSD

Endosane Pharmaceuticals is taking an essential step towards realising its vision for the future: In addition to the already advanced development of the cannabinoid-based compound for the treatment of schizophrenia, Endosane is vigorously investigating further compounds in its own portfolio for the treatment of other mental disorders. Unlike the potential schizophrenia drug, the development of these compounds are still in the so-called preclinical phase, but existing data on related molecules strongly indicate the potential clinical efficacy. If successful, the imminent studies will constitute a solid basis for rapid further development. Endosane is aiming to start clinical trials within 2022.

Post-traumatic stress disorders are a group of mental disorders that are widespread and all characterised by the experience of significant trauma. Those affected are permanently restricted in their way of life. There are often considerable impairments of sleep and the re-experiencing of traumatic life situations. According to the current research, PTSD is caused by an overload of the brain’s processing capacities for dealing with the negative memories created by the trauma, which can resurface in an uncontrolled manner. Currently, available medications are primarily aimed at helping people cope with the symptoms they are experiencing, particularly anxiety, panic attacks, and sleep disorders. 

Support for processing the trauma

Like all the other active pharmaceuticals in Endosane’s portfolio, the molecules in question act via the body’s own endocannabinoid system. However, unlike other active ingredients, these are not cannabinoids but synthetic molecules that alter the concentration of the body’s own endocannabinoids by inhibiting certain enzymes. The development of these molecules was based on various basic research studies in memory research, which showed a connection between changes in the balance of the body’s endocannabinoid system and the ability to process memories. The results suggest that it is possible to influence the processing of trauma by targeting this system. Therefore, the new compounds would not primarily treat the visible symptoms of PTSD, such as anxiety, panic attacks and insomnia, but the root cause, which is the processing of negative memories. 

“We see the endocannabinoid system, as with our active substance for the treatment of schizophrenia, as a modulator of the neurophysiological balance that is offering the possibility of addressing not only the visible symptoms, but the cause itself,” says Prof. Dr. Leweke, Medical Director of Endosane Pharmaceuticals. Even more importantly, the use of the endocannabinoid system would intervene much more ‘gently’ in the neurophysiological structure of the patient than currently available drugs. The chance of considerably reduced side effects is therefore significant. 

Collaboration with UCI

It is no coincidence that the upcoming studies are being carried out at UCI. Prof. Dr. Daniele Piomelli is responsible for research in this field. Like Prof. Leweke, Prof. Piomelli is a pioneer in the field of study into the endocannabinoid system. In particular, the drug class being researched – so-called FAAH-inhibitors – was co-developed by him. “We are very pleased to be able to explore these compounds together with Prof. Piomelli at UCI,” said Max Narr, Managing Director of Endosane Pharmaceuticals. “We are very optimistic that the preclinical studies will provide a clear indication regarding efficacy. If this assumption is confirmed, we will aim to conduct a Phase I clinical trial within the next year.” 

 

About Endosane Pharmaceuticals
Endosane Pharmaceuticals GmbH is a pharmaceutical company based in Berlin aiming to develop and commercialise new finished drugs to treat neurological, neuropsychiatric, and psychiatric conditions. Therefore, Endosane is systematically exploring the endocannabinoid system for its potential to modulate neurophysiological balance. The current compound portfolio contains compounds for treating several indications, including schizophrenia, social anxiety disorder, and post-traumatic stress disorder. More information at www.endosane.com
 
About Prof. Dr. Daniele Piomelli
Prof. Dr. Piomelli is a Professor of Anatomy and Neurobiology at the School of Medicine. He holds the Louise Turner Arnold Chair in Neurosciences and joint appointments at the Biological Chemistry and Pharmacology departments. He is also a director at the Institute for the Study of Cannabis and Editor-in-Chief of “Cannabis and Cannabinoid Research”.

Categories
Sanity Group

Sanity Group appreciates the controlled dispensing of cannabis as stated in the coalition agreement

“We are delighted that SPD, Bündnis 90/Die Grünen and FDP have agreed on the legalisation of cannabis for recreational use via controlled distribution to adults. We have been advocating a more liberal and responsible approach to cannabis for many years and firmly believe that a controlled dispensing is the right way forward. In this way, not only can the black market be curbed and product quality ensured, but youth and consumer protection can also be guaranteed through expert education and advice. The parties of the new German government have now laid the foundation, but the details still need to be worked out: Clear legislation and regulation are needed to define, among other things, the conditions for cultivation, processing, logistics and licensed distribution, thus ensuring quality and supply security. Here, we can also learn from the experience of other countries, such as Canada or the USA. Youth protection and prevention are also elementary and indispensable. We are clearly in favour of the revenue from a potential cannabis tax flowing into youth protection as well as target group-specific educational measures,” says Finn Hänsel, founder of the Sanity Group, who can very well imagine setting up and operating a system of licensed specialist stores. At the same time, the 39-year-old would like the planned legalisation to also uniformly regulate the handling of CBD products in Germany: “Here, we have had an unclear legal situation for all parties involved for years – this topic should now also be addressed in a future law.”

Fabian Friede, who founded Sanity Group together with Hänsel in 2018 and is also CEO of the pharmaceutical subsidiary Vayamed, adds: “The supply of patients with medical cannabis must not be restricted or jeopardised by a future controlled dispensing to adults for consumption purposes. We advocate that the medical cannabis market be clearly separated from the recreational cannabis market, which can be achieved through licensed stores.” In addition, Friede would like to see a simplified prescription of medical cannabis: “The authorisation requirement of health insurance companies must be abolished to make it easier for patients to access therapy with medical cannabis.”


About Sanity Group

The Berlin-based Sanity Group aims to improve people’s quality of life through the sensible use of cannabinoids and the utilisation of the endocannabinoid system. In addition to pharmaceuticals, the focus is also on wellbeing and cosmetic products based on cannabinoids. In parallel, Sanity Group is also working and researching new medical products, innovative dosage forms, and technological products and services to further develop the infrastructure. Sanity Group was founded in 2018 by Finn Age Hänsel and Fabian Friede and now employs a team of over 120 people. Sanity Group includes Vayamed (medical cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), Belfry Medical (medical products), Sanatio CBD, VAAY (CBD products) and This Place (functional natural cosmetics), among others. For more information, visit: sanitygroup.com.

Categories
Sanity Group

Sanity Group Closes $3.5M Follow-On Investment by Casa Verde Capital

“We are proud to welcome Casa Verde as our latest shareholder and we are delighted to have the backing of the cannabis industry’s pre-eminent venture firm. Casa Verde’s commitment to Sanity Group and to Germany further confirms we are on the right strategic path. It is also evidence of growing momentum in the European market as more countries move to initiate pilot projects to legalize and improve access to medical cannabis programs,” says Finn Hänsel, founder and managing director of Sanity Group.

Fabian Friede, who co-founded the company with Hänsel in 2018, adds: “We are excited to benefit from Casa Verde’s vast expertise and experience in the US cannabis market. Yoni Meyer and Karan Wadhera have been a crucial part of our journey since the announcement of our seed round two years ago. We are now pleased to officially expand our collaboration with them through Casa Verde’s direct stake in our business.”

Sanity Group will use the additional investment to advance medical cannabis research and expand its own business, including the development and distribution of medical cannabis and finished medicinal products, as well as its consumer health division through its VAAY and This Place brands.

“We have watched Sanity Group’s growth trajectory closely for the last two years. The Company’s leadership, track record and vision clearly set it on the right path to becoming a leading European cannabis brand,” says Yoni Meyer, Partner at Casa Verde.

Casa Verde joins Sanity Group’s notable investor community, including Swiss VC Redalpine, German HV Capital, Calyx, SevenVentures, Bitburger Ventures, and prominent business angels such as Black Eyed Peas frontman Will.i.am, Hollywood actress Alyssa Milano, music producer Scooter Braun and German soccer player Mario Götze.

 

About Sanity Group
Sanity Group aims to improve people’s quality of life through the sensible use of cannabinoids and the utilization of the endocannabinoid system. In addition to pharmaceuticals, the focus is also on wellbeing and cosmetic products based on cannabinoids. Sanity Group was founded in 2018 by Finn Age Hänsel and Fabian Friede and now employs a team of over 120 people.

About Casa Verde 
Casa Verde is the leading venture capital firm focusing on the cannabis industry. As both the domestic and international cannabis markets continue to evolve and mature, Casa Verde maintains a view that the cannabis industry will be among the most compelling investment themes of our generation.